Archive · 25 Jun 2025
Cipla Reports FY25 Growth and Targets Expansion in FY26
Cipla, a big drug company, is planning to grow by buying other companies and launching new medicines.
They made more money last year, with sales up 7%.
They sell a lot in North America, where they made over $900 million.
Cipla also got 22 new patents for their medicines and introduced 133 new products.
In India, their sales also went up by 7%.
They have factories in India and the US that are making more medicines.
The company also paid out a special dividend to celebrate their 90th anniversary.
Cipla is targeting growth with inorganic expansion and product launches.
The company's FY25 revenue increased by 7% YoY.
North America is Cipla's largest foreign market, with $934 million in revenue in FY25.
Cipla reported 22 patent grants and launched 133 products globally in FY25.
The company's domestic business grew by 7% and crossed the Rs 11,000 crore revenue mark.
- Who
- Cipla, a pharmaceutical company.
- What
- Cipla's financial performance and future plans.
- When
- FY25 and the plans for FY26.
- Where
- India, North America and other global locations.
- Why
- To increase its revenue and market share.
- FY25 Revenue
- Rs 27,548 crore
- FY25 PAT
- Rs 5273 crore
- North America Revenue
- $934 million
- Domestic Business Revenue
- Over Rs 11,000 crore
- Patent Grants FY25
- 22
- Market Cap
- Rs 1.22 trillion